STERIS plc (NYSE:STE) Receives $273.50 Average PT from Analysts

STERIS plc (NYSE:STE) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $273.50.

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th.

Insider Activity at STERIS

In other news, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction on Monday, October 6th. The shares were sold at an average price of $241.82, for a total transaction of $38,449.38. Following the completion of the sale, the chief executive officer directly owned 51,096 shares in the company, valued at approximately $12,356,034.72. The trade was a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the sale, the vice president directly owned 33,669 shares in the company, valued at $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 25,203 shares of company stock valued at $6,624,667 over the last 90 days. Company insiders own 1.07% of the company’s stock.

Hedge Funds Weigh In On STERIS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd acquired a new position in shares of STERIS in the first quarter valued at about $349,950,000. Norges Bank purchased a new stake in STERIS in the second quarter valued at approximately $289,132,000. AQR Capital Management LLC increased its holdings in STERIS by 178.6% in the 3rd quarter. AQR Capital Management LLC now owns 1,183,070 shares of the medical equipment provider’s stock worth $291,704,000 after buying an additional 758,423 shares during the period. Boston Partners acquired a new position in STERIS in the 3rd quarter worth approximately $158,982,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in STERIS by 55.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider’s stock valued at $344,617,000 after acquiring an additional 540,999 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

STE stock opened at $251.72 on Tuesday. STERIS has a one year low of $200.98 and a one year high of $268.60. The firm has a market cap of $24.71 billion, a price-to-earnings ratio of 36.17 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The firm has a 50-day simple moving average of $251.25 and a two-hundred day simple moving average of $243.83.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the business posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, equities analysts forecast that STERIS will post 9.08 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a dividend of $0.63 per share. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio is 36.21%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.